Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference (RNAi). Its pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. The company's clinical development programs include Patisiran, which is in Phase III clinical trial for the treatment of hereditary transthyretin-mediated amyloidosis; Givosiran that is in Phase III trial to treat acute hepatic porphyrias; Fitusiran, an investigational RNAi therapeutic that is in Phase II open-label extension and Phase III clinical trial for the treatment of hemophilia and rare bleeding disorders; and Inclisiran, which is in III clinical trial for hypercholesterolemia. Its clinical programs also include ALN-TTRsc02, an investigational RNAi therapeutic targeting TTR, which is in the Phase I clinical trial for the treatment of various forms of ATTR amyloidosis; Lumasiran (ALN-GO1) that is in Phase I/II clinical trial for the treatment of primary hyperoxaluria type 1; and Cemdisiran (ALN-CC5), which is in the Phase II clinical trial for the treatment of complement-mediated diseases. The company has strategic alliances primarily with Sanofi Genzyme; The Medicines Company; Monsanto Company; Takeda Pharmaceutical Company Limited; Ionis Pharmaceuticals, Inc; and Regeneron Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone617-551-8200
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$74.91 million
Profitability
Miscellaneous
Employees749
OptionableOptionable
Alnylam Pharmaceuticals (NASDAQ:ALNY) Frequently Asked Questions
What is Alnylam Pharmaceuticals' stock symbol?
Alnylam Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALNY."
How were Alnylam Pharmaceuticals' earnings last quarter?
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) released its earnings results on Thursday, February, 7th. The biopharmaceutical company reported ($2.09) earnings per share for the quarter, topping the Zacks' consensus estimate of ($2.27) by $0.18. The biopharmaceutical company had revenue of $21 million for the quarter, compared to analyst estimates of $18.03 million. Alnylam Pharmaceuticals had a negative net margin of 1,016.58% and a negative return on equity of 50.82%. The business's quarterly revenue was down 44.6% compared to the same quarter last year. During the same period in the prior year, the firm earned ($1.20) earnings per share. View Alnylam Pharmaceuticals' Earnings History.
When is Alnylam Pharmaceuticals' next earnings date?
What price target have analysts set for ALNY?
17 Wall Street analysts have issued 1-year price targets for Alnylam Pharmaceuticals' stock. Their predictions range from $63.00 to $230.00. On average, they anticipate Alnylam Pharmaceuticals' share price to reach $133.00 in the next twelve months. This suggests a possible upside of 71.1% from the stock's current price. View Analyst Price Targets for Alnylam Pharmaceuticals.
What is the consensus analysts' recommendation for Alnylam Pharmaceuticals?
17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alnylam Pharmaceuticals in the last year. There are currently 1 sell rating, 3 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Alnylam Pharmaceuticals.
What are Wall Street analysts saying about Alnylam Pharmaceuticals stock?
Here are some recent quotes from research analysts about Alnylam Pharmaceuticals stock:
- 1. Cantor Fitzgerald analysts commented, ": We reiterate our Overweight rating and 12-month price target of $135. Alnylam reported 4Q18 earnings that had few surprises, with Onpattro revenues of $12.1M coming in slightly above the $11-12M range pre- announced in early January. We remain bullish on the Onpattro launch, but think near-term focus in 2019 is on 1) late-stage pipeline readouts and 2) the next wave of programs entering the clinic. ALNY remains a top franchise pick in 2019. The company reiterated strong 4Q Onpattro launch metrics, but did not comment on how 1Q trends are tracking or provide 2019 sales guidance." (2/7/2019)
- 2. According to Zacks Investment Research, "Although we are pleased with Alnylam’s broad and promising pipeline, we note that most candidates are in their early or mid stages of development. These candidates still have a long way to go before hitting the market. Currently, Alnylam depends heavily on Onpattro (patisiran) for growth. Sales of Onpattro in the first quarter of its launch was slow. However, the approval of Onpattro, a first-of-its-kind RNA interference (RNAi) therapeutic, in the United States and Europe was a signficant boost for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults.. Apart from Onpattro, the company has other candidates in late-stage studies, which if approved will also generate revenues. Loss estimates have narrowed ahead of the Q4 earnings. The company has an average negative surprise history." (1/17/2019)
- 3. Needham & Company LLC analysts commented, "Alnylam is expected to announce results of an interim analysis of the Phase 3 trial of givosiran in Acute Hepatic Porphyrias (AHP) later this month. The FDA has reportedly indicated that a statistically significant reduction in biomarker urine ALA level w/ the first 30 enrolled patients may be sufficient for accelerated approval. We expect a positive outcome based on strength of data collected from Phase 1/2 testing, in which profound and durable reductions in urine ALA levels were observed. Mgmt has guided for NDA submission by YE18. We assume U.S. commercial launch in 2H19 and WW peak sales $600-700M. Reiterate BUY." (9/13/2018)
- 4. BMO Capital Markets analysts commented, "We do not see earnings as the most meaningful indicator of value for a development-stage biotech. Revance remains on track to report results from the long-term safety study (SAKURA 3) of RT-002 in glabellar lines in 4Q18. Following this, Revance is expected to file its BLA for RT-002 in glabellar lines in 1H19. We continue to see RT-002 as a differentiated long duration neurotoxin that has the potential to seriously challenge the current market order." (8/3/2018)
Has Alnylam Pharmaceuticals been receiving favorable news coverage?
Media stories about ALNY stock have been trending positive recently, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Alnylam Pharmaceuticals earned a media sentiment score of 2.5 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 6.0 out of 10, meaning that recent press coverage is somewhat likely to have an effect on the stock's share price in the next few days.
Who are some of Alnylam Pharmaceuticals' key competitors?
Some companies that are related to Alnylam Pharmaceuticals include Takeda Pharmaceutical (TKPYY), ASTELLAS PHARMA/ADR (ALPMY), Alexion Pharmaceuticals (ALXN), Shiseido (SSDOY), Teva Pharmaceutical Industries (TEVA), UCB (UCBJF), Mylan (MYL), BioMarin Pharmaceutical (BMRN), Ono Pharmaceutical (OPHLF), Merck KGaA (MKGAF), GRIFOLS S A/S (GRFS), Sarepta Therapeutics (SRPT), Genmab A/S (GNMSF), Bausch Health Companies (BHC) and Beigene (BGNE).
Who are Alnylam Pharmaceuticals' key executives?
Alnylam Pharmaceuticals' management team includes the folowing people:
- Dr. John M. Maraganore, CEO & Exec. Director (Age 56)
- Mr. Barry E. Greene, Pres (Age 56)
- Mr. Manmeet Singh Soni, Sr. VP ,CFO & Principal Accounting Officer (Age 41)
- Dr. Yvonne Greenstreet, Exec. VP & COO (Age 56)
- Dr. Akshay K. Vaishnaw, Pres of R&D (Age 56)
Who are Alnylam Pharmaceuticals' major shareholders?
Alnylam Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.07%), Baillie Gifford & Co. (4.69%), BB Biotech AG (1.55%), First Trust Advisors LP (1.16%), Geode Capital Management LLC (0.90%) and Northern Trust Corp (0.53%). Company insiders that own Alnylam Pharmaceuticals stock include Akshay Vaishnaw, Barry E Greene, Dennis A Ausiello, John Maraganore, Laurie Keating, Michael Mason, Paul Schimmel, Philip A Sharp, Sanofi and Yvonne Greenstreet. View Institutional Ownership Trends for Alnylam Pharmaceuticals.
Which major investors are selling Alnylam Pharmaceuticals stock?
ALNY stock was sold by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Great Point Partners LLC, Los Angeles Capital Management & Equity Research Inc., Two Sigma Advisers LP, Rhenman & Partners Asset Management AB, Mackenzie Financial Corp, Neuburgh Advisers LLC and Bank of New York Mellon Corp. Company insiders that have sold Alnylam Pharmaceuticals company stock in the last year include Akshay Vaishnaw, Barry E Greene, John Maraganore, Laurie Keating, Paul Schimmel, Philip A Sharp and Yvonne Greenstreet. View Insider Buying and Selling for Alnylam Pharmaceuticals.
Which major investors are buying Alnylam Pharmaceuticals stock?
ALNY stock was purchased by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., First Trust Advisors LP, BB Biotech AG, Frontier Capital Management Co. LLC, Bank of Nova Scotia, Sectoral Asset Management Inc, Hsbc Holdings PLC and Westfield Capital Management Co. LP. Company insiders that have bought Alnylam Pharmaceuticals stock in the last two years include Laurie Keating and Sanofi. View Insider Buying and Selling for Alnylam Pharmaceuticals.
How do I buy shares of Alnylam Pharmaceuticals?
Shares of ALNY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Alnylam Pharmaceuticals' stock price today?
One share of ALNY stock can currently be purchased for approximately $77.75.
How big of a company is Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals has a market capitalization of $8.26 billion and generates $74.91 million in revenue each year. The biopharmaceutical company earns $-761,490,000.00 in net income (profit) each year or ($7.57) on an earnings per share basis. Alnylam Pharmaceuticals employs 749 workers across the globe.
What is Alnylam Pharmaceuticals' official website?
How can I contact Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals' mailing address is 300 THIRD STREET, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-551-8200 or via email at [email protected]
MarketBeat Community Rating for Alnylam Pharmaceuticals (NASDAQ ALNY)
MarketBeat's community ratings are surveys of what our community members think about Alnylam Pharmaceuticals and other stocks. Vote "Outperform" if you believe ALNY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALNY will underperform the S&P 500 over the long term. You may vote once every thirty days.
